Abstract

Monitor Immune Responses in Tumor Microenvironment by Next Generation Sequencing

Dennis Huang, Product Manager, Thermo Fisher Scientific

The composition of tumor microenvironment (TME) is highly variable and complex, it often found related to drug response, such as immune checkpoint or CAR-T therapy. How to characterize the TME in an efficient way become more and more important. Besides tumor cells, certain types of cells from immune system plays a critical role when fighting cancer, for example, dendritic cells (DCs) and T cells are capable of activating anti-tumor responses. However, certain cancer cells may induce an immunosuppressive reaction in TME and then weaken the anti-cancer responses even one is treated with immunotherapy. During the session, we will be discussing our latest NGS panel Oncomine Immune Response Research Assay and Ion Ampliseq Immune Repertoire Assay, which can facilitate the research to understand the TME, in order to help resolves the issues and even to predict the responses to immunotherapies.